Pay in 4 interest-free payments of $7.42 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
this effect disappears when you stop taking the drug
Potentially first-in-Class Anti-Myostatin Approach: Blocks myostatin (GDF8), a negative regulator of muscle growth, to preserve and enhance lean mass
Among the marketed large molecule injectable GLP-1 agonists, semaglutide, apart from weight-loss, is being studied for kidney disease and tirzepatide (a dual GLP-1 and GIP receptor agonist) is being evaluated for sleep apnea in Ph 3 clinical trials
Functional nutrition brands are helping normalize the category through direct-to-consumer education and product bundling
STEP-1 Trial
US$ 20.45
US$ 21.81
US$ 29.79
US$ 22.04
US$ 22.51
US$ 28.31
